Annual report
2413.TEDINET S100OJCD
Period2021-04-01 → 2022-03-31
Filed2022-06-29
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥208.2bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥169.2bn | 2020-04-01 → 2021-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥131.0bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥113.1bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥94.5bn | 2017-04-01 → 2018-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥95.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥58.0bn | 2020-04-01 → 2021-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥96.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥58.3bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥34.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥30.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥27.5bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥63.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥37.8bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥21.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥19.6bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥18.1bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥66.1bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥41.2bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥346.0bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥273.1bn | at 2021-03-31 | Cons. | Assets IFRS |
| Total assets | ¥221.8bn | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥137.3bn | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥116.4bn | at 2018-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥82.0bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥65.9bn | at 2021-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥264.0bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥207.3bn | at 2021-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥171.6bn | at 2020-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥257.8bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥199.8bn | at 2021-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥166.1bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥98.7bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥82.5bn | at 2018-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥104.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥89.1bn | at 2021-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥47.9bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥27.5bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥23.7bn | at 2018-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥52.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥46.6bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥26.8bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥17.7bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥15.9bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥23.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥3.6bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥49.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥8.8bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥7.3bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥16.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥11.6bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥43.4bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥5.0bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥4.8bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥94.06 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥55.73 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥31.89 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥30.22 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥27.99 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥93.98 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥55.68 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥31.88 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥30.2 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥27.97 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥378.75 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥293.64 | at 2021-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥244.24 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥151.97 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥126.97 | at 2018-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 74.5% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.2% | at 2021-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.9% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.9% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 70.8% | at 2018-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 27.9% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 20.7% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 16.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 21.6% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 24.2% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 9,384 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 8,249 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 7,127 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 6,024 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 5,165 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥55.7bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥49.9bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥27.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥22.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥22.2bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥27.5bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥28.0bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥32.3bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥30.8bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.7bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥12.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.6bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥28.6bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥30.7bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥20.5bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥22.0bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥12.2bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥8.9bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.0bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥215.4bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥195.4bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥163.2bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥97.8bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥83.9bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥62.9bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥55.6bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥152.5bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥139.8bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥122.9bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥65.8bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥59.0bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥92.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥80.3bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥30.17 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.41 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.03 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.67 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.52 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥30.15 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥32.38 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥18.02 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥13.66 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥18.51 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥16 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥8.5 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥7 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥11 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥223.54 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥205.3 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥180.54 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥101.23 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥90.65 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 70.4% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.3% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.0% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 14.1% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.8% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.2% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 21.8% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 678,904,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,785,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 678,645,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 647,957,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 323,897,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 574 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 554 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 473 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 421 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 364 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 60
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥5.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥5.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥2.3bn |
| Career Solutionreportable segment | employees | at 2022-03-31 | 627 pure |
| Career Solutionreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥14.1bn |
| Career Solutionreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥13.4bn |
| Career Solutionreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥740m |
| Career Solutionreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥4.6bn |
| Evidence Solutionreportable segment | employees | at 2022-03-31 | 2181 pure |
| Evidence Solutionreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥22.8bn |
| Evidence Solutionreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥21.9bn |
| Evidence Solutionreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥856m |
| Evidence Solutionreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥5.7bn |
| Medical Platformreportable segment | employees | at 2022-03-31 | 1754 pure |
| Medical Platformreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥85.9bn |
| Medical Platformreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥83.2bn |
| Medical Platformreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥2.7bn |
| Medical Platformreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥39.6bn |
| Overseasreportable segment | employees | at 2022-03-31 | 2117 pure |
| Overseasreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥51.8bn |
| Overseasreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥51.8bn |
| Overseasreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥20m |
| Overseasreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥44.8bn |
| Site Solutionreportable segment | employees | at 2022-03-31 | 2470 pure |
| Site Solutionreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥35.2bn |
| Site Solutionreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.7bn |
| Site Solutionreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥525m |
| Site Solutionreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥3.4bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥209.8bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥204.9bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥4.9bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥98.1bn |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥2.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥2.9bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥2.4bn |
| Career Solutionreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥13.5bn |
| Career Solutionreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥13.5bn |
| Career Solutionreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥46m |
| Career Solutionreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥3.8bn |
| Evidence Solutionreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥19.5bn |
| Evidence Solutionreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥19.0bn |
| Evidence Solutionreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥520m |
| Evidence Solutionreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥3.6bn |
| Medical Platformreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥77.1bn |
| Medical Platformreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥74.8bn |
| Medical Platformreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥2.3bn |
| Medical Platformreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥37.9bn |
| Overseasreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥42.1bn |
| Overseasreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥42.1bn |
| Overseasreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥14m |
| Overseasreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥12.6bn |
| Site Solutionreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥16.6bn |
| Site Solutionreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥16.6bn |
| Site Solutionreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥1m |
| Site Solutionreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥1.5bn |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥168.8bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥166.0bn |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥2.8bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥59.4bn |
| Medical Platformreportable segment | employees | at 2022-03-31 | 479 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,643
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 7259000 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.011 | |
| Number of shares held | CurrentYearInstant | 492534000 | |
| Shareholding ratio | CurrentYearInstant | 0.725 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 45000 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 678739600 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 6787396 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 120000 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 678904600 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 6787396 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 45000 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 45000 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0001 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 45000 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 45000 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0001 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 10862000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 16.0 | |
| Number of male directors and other officers | FilingDateInstant | 5 | |
| Number of female directors and other officers | FilingDateInstant | 4 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.444 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05425-000TanimuraItaruMember | 19466000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05425-000TomaruAkihikoMember | 401000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05425-000TsuchiyaEijiMember | 35000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05425-000IzumiyaKazuyukiMember | 16000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05425-000NakamuraRieMember | 21000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05425-000YoshidaKenichiroMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05425-000YamazakiMayukaMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05425-000EbataTakakoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05425-000ToyamaRyokoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 19938000 | |
| Audit fees reporting company | Prior1YearDuration | 49000000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | － | JPY |
| Audit fees reporting company | CurrentYearDuration | 56000000 | JPY |
| Non audit fees reporting company | CurrentYearDuration | 0 | JPY |
| Audit fees consolidated subsidiaries | Prior1YearDuration | 42000000 | JPY |
| Non audit fees consolidated subsidiaries | Prior1YearDuration | 15000000 | JPY |
| Audit fees consolidated subsidiaries | CurrentYearDuration | 65000000 | JPY |
| Non audit fees consolidated subsidiaries | CurrentYearDuration | 9000000 | JPY |
| Audit fees total | Prior1YearDuration | 91000000 | JPY |
| Non audit fees total | Prior1YearDuration | 15000000 | JPY |
| Audit fees total | CurrentYearDuration | 121000000 | JPY |
| Non audit fees total | CurrentYearDuration | 9000000 | JPY |
| Audit fees reporting company network firms | Prior1YearDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |